Reviews/GLP-1 Receptor Agonists/Improve non-alcoholic fatty liver disease
Metabolic · GLP1-MET-03 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Across this corpus, large blinded trials show that two of these drugs, semaglutide and the dual-acting tirzepatide, help the liver heal in people with fatty-liver disease: more patients had their steatohepatitis resolve on the drug than on placebo [1][3][4]. A big Phase 3 semaglutide trial also showed a reduction in liver scarring [4], though an earlier smaller semaglutide trial did not improve scarring significantly [1]. Separate imaging and ultrasound studies show the drugs cut the amount of fat in the liver [9][16]. The benefit was not seen in patients who already had cirrhosis, where semaglutide did no better than placebo [6]. The panel also noted that the human histology evidence covers only semaglutide and tirzepatide, not the wider class of drugs the claim names, and that most of the semaglutide trials were funded by one company.
Three independent double-blind randomised trials, including a Phase 3 trial, show significant resolution of steatohepatitis versus placebo: 59% vs 17% for semaglutide 0.4 mg [1], up to 62% vs 10% for tirzepatide [3], and 62.9% vs 34.3% in the Phase 3 semaglutide trial [4]. The Phase 3 trial also reported fibrosis reduction of 36.8% vs 22.4% [4], and tirzepatide improved fibrosis stage (for example 55% vs 30% at 5 mg) [3]. Liver-fat reduction is documented directly by MRI-PDFF, with a least-squares mean change of −8.0% on semaglutide monotherapy [9], and by ultrasound, with steatosis improving in 70% of patients [16]. A real-world cohort additionally found liver stiffness fell from a median of 4.85 to 3.9 kPa on semaglutide [21]. The contested point: The evidence divides on two axes: scope and stage. Fibrosis-stage improvement was non-significant in the Phase 2 semaglutide trial (43% vs 33%, P=0.48) [1] even though resolution was robust, and in compensated cirrhosis semaglutide produced no significant benefit, with a point estimate favouring placebo [6]. The histological evidence also covers only semaglutide [1][4] and tirzepatide [3], narrower than the class-level wording of the claim.
All 21 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from GLP-1 Receptor Agonists, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Class-level overreach: human histological evidence exists only for semaglutide [1][4] and the dual GIP/GLP-1R agonist tirzepatide [3]. No human histology data for liraglutide, dulaglutide or exenatide appear in the corpus (liraglutide only in an excluded mouse model), so the class-wide wording outruns the patient-level evidence.
Histological improvement is driven by NASH/MASH resolution; fibrosis-stage improvement is inconsistent — the Phase 2 semaglutide trial [1] reported 43% vs 33% (P=0.48), non-significant. 'Improve histological outcomes' is only partially supported for the fibrosis component.
Where it remains uncertain. Fibrosis-stage improvement was non-significant in one Phase 2 trial (43% vs 33%, P=0.48) [1], and in NASH-related cirrhosis semaglutide did not significantly improve fibrosis or resolution [6].
Aleatory
The null in compensated cirrhosis rests on only 71 patients [6], so chance variation cannot be separated from a true absence of effect.
Epistemic
Liraglutide, dulaglutide and exenatide have no patient-level histology in the corpus; liraglutide appears only in an excluded mouse model [20].
The load-bearing papers from a corpus of 21, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Phase 2 RCT dose-related histological resolution with semaglutide
“The percentage of patients in whom NASH resolution was achieved with no worsening of fibrosis was 40% in the 0.1-mg group, 36% in the 0.2-mg group, 59% in the 0.4-mg group, and 17% in the placebo group (P<0.001 for semaglutide 0.4 mg vs. placebo).”
Panel auditInternal validity: high · scope of inference: Biopsy-confirmed NASH with F1–F3 fibrosis; histological NASH resolution over 72 weeks.Key limitations: phase 2 · fibrosis-stage improvement not significant (43% vs 33%, P=0.48) · neoplasm imbalance noted
Independent RCT of a second GIP/GLP-1 receptor agonist confirming histological resolution
“The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10% in the placebo group, 44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50), 56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62), and 62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69) (P<0.001 for all three comparisons).”
Panel auditInternal validity: medium · scope of inference: Biopsy-confirmed MASH with F2/F3 fibrosis over 52 weeks.Key limitations: dual GIP/GLP-1 agonist so effect not attributable to GLP-1R alone · phase 2, dose-finding · imputation of missing biopsies
Phase 3 RCT evidence that semaglutide improves histological resolution of MASH versus placebo
“A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group (estimated difference, 14.4 percentage points; 95% CI, 7.5 to 21.3; P<0.001).”
Panel auditInternal validity: high · scope of inference: Biopsy-defined MASH with fibrosis stage 2 or 3; 72-week interim histology.Key limitations: planned interim analysis of first 800 of 1197 · clinical-outcome part (part 2) not yet reported
3 of 21 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Converging placebo-controlled RCT evidence including a Phase 3 trial establishes histological benefit and liver-fat reduction for GLP-1-active agonists, placing the claim at the lower edge of Established despite stage-specific and class-generalisation caveats.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Histology for pure GLP-1 RAs. The class-level claim has no biopsy evidence for liraglutide, dulaglutide or exenatide in patients; only semaglutide [1][4] and tirzepatide [3] are covered. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Placebo-controlled biopsy trials of a pure GLP-1 RA such as liraglutide or dulaglutide in biopsy-confirmed MASH.
Open question: Do GLP-1 receptor agonists other than semaglutide improve liver histology in patients with MASH? Why it is still open: The corpus contains human histology only for semaglutide [1][4] and the dual agonist tirzepatide [3]; other agents appear only in excluded animal models.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19